EICHORPublic-registry site landscape for NCT03938740, “Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec”, a Diabetes Mellitus, Type 1 study sponsored by Diasome Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03938740 (registry record) |
| Study title | Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec |
| Official title | An Exploratory Randomized Open-Label 2-Arm Comparison of Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec to Determine Optimum Basal Insulin Dosing Regimens in Type 1 Diabetes Mellitus Subjects |
| Sponsor | Diasome Pharmaceuticals |
| Condition(s) | Diabetes Mellitus, Type 1 |
| Phase | PHASE2 |
| Listed sites | 7 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03938740.
Eichor generates a preliminary site-risk snapshot for NCT03938740 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diabetes Mellitus, Type 1 trials
More from Diasome Pharmaceuticals
← Eichor home · All tracked trials · Diabetes Mellitus, Type 1 studies · Weekly briefs
